Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia
نویسندگان
چکیده
منابع مشابه
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete remission (CR1). Patients with AML (16-60 years) in CR1 after 2 cycles of intensive chemotherapy and not eligible for allogeneic SCT were randomized between intensive chemo...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Autologous peripheral blood stem cell transplantation for acute myeloid leukemia
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia Edo Vellenga,1 Wim van Putten,2 Gert J. Ossenkoppele,3 Leo F. Verdonck,4 Matthias Theobald,5 Jan J. Cornelissen,6 Peter C. Huijgens,3 Johan Maertens,7 Alois Gratwohl,8 Ron Schaafsma,9 Urs Schanz,10 Carlos Graux,11 Harry C. Schouten,12 Augustin Ferrant,13 Mario Bargetzi,14 Martin F. Fey,15 and Bob Löwenberg,6 for th...
متن کاملAutologous Stem Cell Transplantation for Acute Myeloid Leukemia
In the majority of patients, the therapy of acute myeloid leukemia (AML) has a curative in‐ tent and includes two phases, i.e. induction and consolidation. The former aims at complete remission (CR) achievement, the latter at the eradication of residual leukemic cells, which are undetectable at morphologic examination of bone marrow after induction therapy in pa‐ tients in CR. Current induction...
متن کاملHodgkin’s Lymphoma Occurring Secondary to Autologous Stem Cell Transplantation in Plasma Cell Leukemia; A Case Report
Survival of patients with multiple myeloma has improved substantially because of availability of new therapies including autotransplants, immunomodulating drugs and proteasome-inhibitors. Second primary cancers have emerged as an important determinant of morbidity and mortality among cancer survivors. Even though there is an increased risk of new cancers of the lymphoreticular and haematopoetic...
متن کاملAutologous transplantation therapy for chronic myelogenous leukemia.
even clinical relapses sometimes occurring as late as 5 to 10 T years after transplantation is being recognized in recipients HE TERM CHRONIC myelogenous leukemia (CML) belies the insidious, unsparing course of this lethal of either T-lymphocyte–depleted or unmanipulated grafts. hematopoietic malignancy. In CML, the malignant transforInterferon-a (IFN-a) therapy for CML. Therapy of mation of a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bone Marrow Transplantation
سال: 1997
ISSN: 0268-3369,1476-5365
DOI: 10.1038/sj.bmt.1700979